Loading...
•
Dec 31, 2020
Iovance Q4 2020 Earnings Report
Iovance reported fourth quarter and full year 2020 financial results, highlighting progress in TIL cell therapies and a strong cash position.
Key Takeaways
Iovance Biotherapeutics reported a net loss for the fourth quarter of 2020 of $68.4 million, or $0.47 per share, and held $635.0 million in cash, cash equivalents, short-term investments, and restricted cash at the end of the year. The company anticipates its cash balance will be sufficient into 2023.
Advanced TIL cell therapies in metastatic melanoma, cervical, head and neck, and non-small cell lung cancers.
Continued dialogue with FDA regarding potency assays for lifileucel.
Cash, cash equivalents, short-term investments and restricted cash totaled $635.0 million at December 31, 2020.
Net loss for the fourth quarter ended December 31, 2020, was $68.4 million, or $0.47 per share.
Forward Guidance
Iovance anticipates that the year-end balance of cash, cash equivalents, short-term investments and restricted cash will be sufficient into 2023 and is in a strong position to continue to execute operating plan and advance portfolio in 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...